246 related articles for article (PubMed ID: 25981525)
21. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.
Lin L; Hanson CV; Alter HJ; Jauvin V; Bernard KA; Murthy KK; Metzel P; Corash L
Transfusion; 2005 Apr; 45(4):580-90. PubMed ID: 15819680
[TBL] [Abstract][Full Text] [Related]
22. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
Ciaravino V; Hanover J; Lin L; Sullivan T; Corash L
Transfusion; 2009 May; 49(5):985-94. PubMed ID: 19175545
[TBL] [Abstract][Full Text] [Related]
23. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
24. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
[TBL] [Abstract][Full Text] [Related]
25. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
[TBL] [Abstract][Full Text] [Related]
26. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
[TBL] [Abstract][Full Text] [Related]
27. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
[TBL] [Abstract][Full Text] [Related]
28. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
[TBL] [Abstract][Full Text] [Related]
29. Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
Infanti L; Stebler C; Job S; Ruesch M; Gratwohl A; Irsch J; Lin L; Buser A
Transfus Apher Sci; 2011 Oct; 45(2):175-81. PubMed ID: 21840762
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
[TBL] [Abstract][Full Text] [Related]
31. Pathogen-reduced platelets in pediatric and neonatal patients: Demographics, transfusion rates, and transfusion reactions.
Lasky B; Nolasco J; Graff J; Ward DC; Ziman A; McGonigle AM
Transfusion; 2021 Oct; 61(10):2869-2876. PubMed ID: 34448199
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.
Ciaravi V; McCullough T; Dayan AD
Hum Exp Toxicol; 2001 Oct; 20(10):533-50. PubMed ID: 11858518
[TBL] [Abstract][Full Text] [Related]
33. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT
Ladaique P; Etienne JM; Pedini P; Chiaroni J; Vey N; Picard C; Chabrieres C
Blood Transfus; 2023 Sep; 21(5):400-408. PubMed ID: 36795348
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
[TBL] [Abstract][Full Text] [Related]
36. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
[TBL] [Abstract][Full Text] [Related]
37. [Feasibility study for Intercept platelets].
Bardiaux L; Vauzou S; Olivier B; Mathieu-Daude D; Durand E; Dite C; Roubinet F
Transfus Clin Biol; 2016 Nov; 23(4):212-216. PubMed ID: 27644172
[TBL] [Abstract][Full Text] [Related]
38. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model.
Corash L; Benjamin RJ
Transfusion; 2016 Mar; 56 Suppl 1():S29-38. PubMed ID: 27001358
[TBL] [Abstract][Full Text] [Related]
39. Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept ™) over a 5-year period of extensive delivery.
Bost V; Chavarin P; Boussoulade F; Fabrigli P; Chabre C; Benamara H; Odent-Malaure H; Legrand D; Cognasse F; Garraud O
Vox Sang; 2015 Nov; 109(4):414-6. PubMed ID: 26031441
[TBL] [Abstract][Full Text] [Related]
40. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.
Snyder E; Raife T; Lin L; Cimino G; Metzel P; Rheinschmidt M; Baril L; Davis K; Buchholz DH; Corash L; Conlan MG
Transfusion; 2004 Dec; 44(12):1732-40. PubMed ID: 15584988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
